Evidence map›Paper›PMID 25779570›Full record

ArticleAntimicrobial agents and chemotherapy2015

Ceftriaxone-resistant Salmonella enterica serotype typhimurium sequence type 313 from Kenyan patients is associated with the blaCTX-M-15 gene on a novel IncHI2 plasmid.

Samuel Kariuki, Chinyere Okoro, John Kiiru, Samuel Njoroge, Geoffrey Omuse, Gemma Langridge, Robert A Kingsley, Gordon Dougan, Gunturu Revathi

Open access · hybridAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
13.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. NontyphoidalOpen forum infectious diseases · 2023
    Article
  10. Prevalence and genomic characterization ofFrontiers in microbiology · 2023
    Article
  11. Article
  12. Review
  13. Article
  14. Detection of multidrug-resistantVeterinary world · 2021
    Article
  15. Article
  16. Article
  17. Pathogenic signature of invasive non-typhoidalHuman vaccines & immunotherapeutics · 2020
    Review
  18. Article
  19. Article
  20. Research on Invasive Nontyphoidal Salmonella Disease and Developments Towards Better Understanding of Epidemiology, Management, and Control Strategies.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Samuel KariukiCentre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom samkariuki2@gmail.com.
Chinyere OkoroThe Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom.
John KiiruCentre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.
Samuel NjorogeCentre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.ORCID http://orcid.org/0000-0001-6965-3681
Geoffrey OmuseAga Khan University Hospital, Nairobi, Kenya.
Gemma LangridgeThe Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom.
Robert A KingsleyThe Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom.
Gordon DouganThe Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom.
Gunturu RevathiAga Khan University Hospital, Nairobi, Kenya.
Wellcome Sanger Institute · GBAga Khan University Hospital Nairobi · KEKenya Medical Research Institute · KE

Funding

Integrating geographical and genetic mapping of salmonella disease in an endemicR01AI099525 · NIAID · KENYA MEDICAL RESEARCH INSTITUTE (KEMRI) · PI GUNN, JOHN S, KARIUKI, SAMUEL M · 2013 to 2024
$1.3M
NIAID NIH HHS 1R01AI099525NIAID NIH HHS R01 AI099525Wellcome Trust
6 · The paper itself

Abstract

Multidrug-resistant bacteria pose a major challenge to the clinical management of infections in resource-poor settings. Although nontyphoidal Salmonella (NTS) bacteria cause predominantly enteric self-limiting illness in developed countries, NTS is responsible for a huge burden of life-threatening bloodstream infections in sub-Saharan Africa. Here, we characterized nine S. Typhimurium isolates from an outbreak involving patients who initially failed to respond to ceftriaxone treatment at a referral hospital in Kenya. These Salmonella enterica serotype Typhimurium isolates were resistant to ampicillin, chloramphenicol, cefuroxime, ceftriaxone, aztreonam, cefepime, sulfamethoxazole-trimethoprim, and cefpodoxime. Resistance to β-lactams, including to ceftriaxone, was associated with carriage of a combination of blaCTX-M-15, blaOXA-1, and blaTEM-1 genes. The genes encoding resistance to heavy-metal ions were borne on the novel IncHI2 plasmid pKST313, which also carried a pair of class 1 integrons. All nine isolates formed a single clade within S. Typhimurium ST313, the major clone of an ongoing invasive NTS epidemic in the region. This emerging ceftriaxone-resistant clone may pose a major challenge in the management of invasive NTS in sub-Saharan Africa.

Indexed as

AmpicillinAnti-Bacterial AgentsBacterial ProteinsCeftriaxoneCefuroximeChloramphenicolDrug Resistance, Multiple, BacterialKenyaMicrobial Sensitivity TestsPlasmidsSalmonella typhimuriumSerogroupAmpicillinAnti-Bacterial AgentsBacterial ProteinsCeftriaxoneCefuroximeChloramphenicol

Identifiers

PMID25779570
PMCPMC4432211
OpenAlexW2118259956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.